Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory in Treating COVID-19 Disease

Phase

Condition

Covid-19

Acute Respiratory Distress Syndrome (Ards)

Common Cold

Treatment

N/A

Clinical Study ID

NCT04412395

COVID-19_LF

Ages 18-80
All Genders

Study Summary

The aim of the study is to clinically use bovine Lf as a safe antiviral adjuvant for treatment and to assess the potential in reducing mortality and morbidity rates in COVID-19 patients. The study was approved by the ethical committee of the Egyptian Center for Research and Regenerative Medicine in 11-5-2020.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Patients tested positive (PCR) for SARS-CoV-2 and clinically symptomatic.
Adult patients with age >18 years.
Patients willing and able to sign the study informed consent form.

Exclusion

Exclusion Criteria:

Critically severe disease patients (having Respiratory failure requiring mechanicalventilation, or signs of septic shock or multiple organ failure requiring ICUadmission).
Patients who are unconscious
Patients who have convulsions
Patients suffering from central cyanosis with SPO2< 90% (for asthmatic patients withSPO2<88%)
Pregnant or lactating women
Patients with a known history of pro-inflammatory diseases (patients with autoimmunediseases, patients receiving chemotherapy for cancer, patients with malabsorption,patients with inflammatory bowel disease, Crohn's disease or ulcerative colitis).
History or suspected immunosuppressive or immunodeficient state including HIVinfection, or chronic immunosuppressant medication (more than 14 days) within the past 3 months (inhaled and topical steroids are allowed).
Patients with severe renal impairment (GFR <60 ml/min/1.73m2 as measured by theCockcroft-Gault formula).
Patient with severe hepatic impairment, biliary cirrhosis or cholestasis
Patients who received immunoregulatory therapy within one month before the start ofthe study.
Patients with Known or suspected allergy or any contraindications to Lactoferrin.
Any condition, according to the judgment of the investigator, would interfere with thepatient's ability to comply with all study requirements or that would place thepatient at unacceptable risk by his/her participation in the study.

Study Design

February 01, 2022

December 30, 2022

Study Description

The World Health Organization (WHO) declared the coronavirus (SARS-CoV-2, COVID-19) outbreak a Public Health Emergency of International Concern with a pandemic spread. The situation is rapidly evolving, which raises the approach of reproposing already approved drugs to meet the emerging challenge and to save time and money. Lactoferrin (Lf) is a natural glycoprotein that broadly distributed within the body fluids and found predominantly in milk. It represents a known component of the innate immune system. The antiviral activity of Lf has been reported against many viruses, including SARS-CoV-1, through blocking the viral receptors on the host cells preventing them from entry and replication. Markedly, data reveals that Lf interacts with Heparan Sulfate Proteoglycans (HSPGs) and Angiotensin Converting Enzyme 2 (ACE2) receptors that are reported as SARS-CoV-2-binding sites to enter the host cell, suggesting a potential significance of Lf as an antiviral against SARS-CoV-2. Moreover, the immunoregulatory effects of Lf can protect against the cytokine-storm and thrombotic complications that result from the COVID-19-induced over-stimulated inflammatory response and exaggerated immune reactions. In addition, Lf can decrease the free iron toxicity caused by the virus as it has a strong iron chelating ability. Lf is a safe approved food supplement that is available in the markets for enhancement of immunity and for treatment of anemia. The aim of this study is to perform a randomized, double-blind, placebo-controlled, two arms, clinical trial to assess oral enteric-coated tablet of bovine apolactoferrin (the low iron-content form of Lf) as a safe antiviral and immunoregulatory therapy in patients diagnosed with COVID-19 disease.

Connect with a study center

National Research Center, Egypt (Clinical and Molecular Pharmacology)
Cairo, Giza 12622
Egypt
Site Not Available
Clinical Trial Unit National Research Center
Cairo,
Egypt
Site Not Available
Clinmax CRO (Clinical Research Organization)
Cairo, 11835
Egypt
Site Not Available
Egyptian Military Medical Services (Hospitals)
Cairo,
Egypt
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.